Dose-response curves for predicting misonidazole-induced peripheral neuropathy

Area of Science:

• Pharmacology
• Toxicology
• Clinical Oncology

Background:

• Misonidazole is a hypoxic cell radiosensitizer used in cancer treatment.
• Peripheral neuropathy is a known dose-limiting toxicity of misonidazole.
• Understanding the pharmacokinetic drivers of this toxicity is crucial for patient safety.

Purpose of the Study:

• To investigate the relationship between pharmacokinetic parameters of misonidazole and the incidence of peripheral neuropathy.
• To identify which pharmacokinetic parameters best predict the probability of developing peripheral neuropathy.

Main Methods:

• Pharmacokinetic data from 27 patients receiving intravenous misonidazole were analyzed.
• Peripheral neuropathy incidence was plotted against various pharmacokinetic parameters.
• Linear logistic regression models were employed to assess correlations.

Main Results:

• A sigmoid relationship was observed between peripheral neuropathy and several pharmacokinetic parameters, including AUC, cumulative dose, plasma concentration, and half-life.
• The area under the curve (AUC) demonstrated the strongest correlation with the probability of peripheral neuropathy.
• Statistical analysis confirmed the significance of these findings.

Conclusions:

• Misonidazole-induced peripheral neuropathy is strongly associated with pharmacokinetic exposure, particularly AUC.
• This pharmacokinetic-toxicity modeling approach can inform dose optimization and toxicity management in cancer therapy.
• The methodology may be applicable to evaluating other toxic agents in oncology.